(Lung Cancer) High Tumor Mutational Burden (TMB) and Its Association with NSCLC Treatment
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
High tumor mutational burden (TMB) in non-small cell lung cancer (NSCLC) patients receiving first-line combination Opdivo (nivolumab) and Yervoy (ipilimumab) was associated with a statistically significant improvement in progression-free survival (PFS).
On February 5, 2018, Ono Pharmaceutical announced the Phase III clinical trial results of CheckMate-227 (NCT02477826), which evaluated first-line treatment combining Yervoy and Opdivo in NSCLC patients.
The CheckMate-227 trial enrolled over 2,500 NSCLC patients and was divided into three parts based on PD-L1 positive, PD-L1 negative, and broader patient background data.
For PD-L1-positive patients: the groups were Opdivo monotherapy, Opdivo + Yervoy combination, and chemotherapy; and Opdivo + chemotherapy combination (Part 1a). For PD-L1-negative patients, the same groupings minus Opdivo monotherapy were used (Part 1b).
The data reported this time focused on patients with high TMB regardless of PD-L1 status, comparing biweekly Opdivo 3 mg/kg + every-six-week Yervoy 1 mg/kg with chemotherapy using PFS as the comparative analysis metric.
TMB was assessed using Foundation Medicine's Foundation One CDx. Among the enrolled patients, 45% had tumor mutational burden ≥10 mut/Mb.
The primary endpoint PFS analysis showed that statistically, the combination of the two drugs was proven to extend PFS.
Based on CheckMate-227 data, Dr. Matthew D. Hellmann stated: Through this trial, the total genomic tumor mutation load — tumor mutational burden (TMB) — was demonstrated to be a biomarker that can indicate immunotherapy activity. Regardless of PD-L1 status, when using Opdivo + Yervoy, TMB can serve as a reference indicator.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4